/
We are a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue utilizing our platform technologies. Our lead product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to abl…
The business is unprofitable at the operating level (-256.27% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 50.7% YoY with margins expanding 53.3pp.
Negative free cash flow of -$38M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$19M
▲ +50.7% YoY
Net Income (TTM)
-$39M
▼ -53.0% YoY
Op. Margin
-202.56%
▲ +53.3pp YoY
ROIC
-52.82%
▲ +2.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$39M
▼ -63.7% YoY
Op. Cash Flow (TTM)
-$39M
▼ -62.9% YoY
Net Debt
-$38M
Net Cash Position
Cash & Equiv.
$50M
Continue Research